Genelux Corporation (GNLX)
$2.32-7.94%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $104M
- Beta
- 0.58
- P/E (TTM)
- -2.61
- Short % float
- 12.07%
- Days to cover
- 20.4
- SI change
- +6.5%
- 1W
- -7.94%
- 1M
- -6.07%
- vs SPY 1W
- -6.96%
- vs SPY 1M
- -7.94%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 1
- GROWTH
- 2
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-117.3%
REV YoY-
ROE-195.4%
EPS YoY-
ROA-129.0%
GROSS-1762
OP-445200
NET-422412
[VALUATION]
P/E TTM-2.61
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B6.47
P/FCF-
EV/EBITDA-2.88
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E15.02
ALTMAN Z-
CURR RATIO2.39
ND/EBITDA-
BETA0.58
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
LOW CONFIDENCE · 14/20
PROFIT FACTOR0.7
TRADES14
[REGIME]FULL HISTORY
CRISIS
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on GNLX?
- LOPJLB’s latest quantitative signal on Genelux Corporation (GNLX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GNLX in?
- Genelux Corporation (GNLX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Genelux Corporation (GNLX) do?
- Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also…